Shortly after sunrise, Artiva Biotherapeutics, Inc. (ARTV Proposed) disclosed the terms for its revived IPO and launched the $130.5 million deal for pricing this week. Artiva Biotherapeutics is offering 8.7 million shares at a price range of $14.00 to $16.00 to raise $130.5 million, if the IPO is priced at the $15.00 mid-point. The market cap would be $263.7 million, assuming mid-point pricing. This is a NASDAQ listing.
Jefferies, TD Cowen, Cantor, Wedbush PacGrow and Needham & Company are the joint book-runners.
Its bankers plan to price Artiva Biotherapeutics’ IPO on Thursday night, July 18, 2024, to trade Friday, July 19, on the NASDAQ.
Artiva Biotherapeutics, based in San Diego, is developing its lead product candidate, AlloNK, an NK (a Natural Killer) cell therapy – in combination with B-cell targeted monoclonal antibodies (mAbs) – in an ongoing Phase 1/1b trial in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. The company expects to report initial data from at least one of those clinical trials in the first half of 2025.
“To our knowledge, AlloNK was the first allogeneic, off-the-shelf NK cell therapy candidate to receive Investigational New Drug application (IND) clearance to be administered to a patient with an autoimmune disease in a U.S. clinical trial, and to receive United States Food and Drug Administration (FDA) Fast Track designation in an autoimmune disease,” the prospectus says.
This IPO represents Artiva Biotherapeutics’ second attempt at going public. The company withdrew its original IPO filing on Nov. 1, 2022, its SEC filings show.
Artiva Biotherapeutics has licensing and collaboration revenue, according to its S-1/A filing.
Its financial statements show a history of net losses – typical for a biotech when it goes public.
Artiva Biotherapeutics reported a net loss of $25.97 million on licensing and collaboration revenue of $32.75 million for the 12 months that ended March 31, 2024, according to financial statements in the prospectus.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on IPOScoop.com’s website.)Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy. |